SCHEMBL8049532

SCHEMBL8049532

CN1CCC(O)(c2ccccc2F)CC1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 7/20 0.60
OPRD1 P41143 7/20 0.60
OPRK1 P41145 7/20 0.60
OPRL1 P41146 7/20 0.60
ALDH1A1 P00352 3/20 0.47
USP2 O75604 2/20 0.47
HPGD P15428 1/20 0.47
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.43
MAPK1 P28482 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GLA P06280 1/20 0.40
HDAC4 P56524 1/20 0.39
NR1D1 P20393 1/20 0.39
NR1D2 Q14995 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10988981 0.90 OPRM1 (0.54) OPRM1OPRD1OPRK1OPRL1ALDH1A1
SCHEMBL10078307 0.86 OPRD1 (0.47) OPRM1OPRD1OPRK1OPRL1ALDH1A1
SCHEMBL23232242 0.82 OPRM1 (0.59) OPRM1OPRD1OPRK1OPRL1ALDH1A1
SCHEMBL8044669 0.81 OPRL1 (0.56) OPRM1OPRD1OPRK1OPRL1ALDH1A1
SCHEMBL10057664 0.81 OPRM1 (0.68) OPRM1OPRD1OPRK1OPRL1ALDH1A1
SCHEMBL10994724 0.80 OPRM1 (0.48) OPRM1OPRD1OPRK1OPRL1ALDH1A1
SCHEMBL6926820 0.80 OPRD1 (0.44) OPRM1OPRD1OPRK1OPRL1HDAC4
SCHEMBL17888234 0.80 OPRM1 (0.62) OPRM1OPRD1OPRK1OPRL1MAPK1
SCHEMBL16838121 0.79 MAPK1 (0.43) OPRM1OPRD1OPRK1OPRL1ALDH1A1
SCHEMBL10990189 0.79 MAPK1 (0.40) OPRM1OPRD1OPRK1OPRL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210317134-A1 UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF RAPT THERAPEUTICS INC (US) 2021-10-14 US disclosed
US-10196376-B2 Hepatitis B antiviral agents NOVIRA THERAPEUTICS, INC. (US) 2019-02-05 US disclosed
US-20170334882-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC 2017-11-23 US disclosed
US-9751857-B2 Hepatitis B antiviral agents NOVIRA THERAPEUTICS, INC. (US) 2017-09-05 US disclosed
EP-2220083-B1 IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS JANSSEN PHARMACEUTICALS INC (US) 2017-07-19 EP disclosed
US-9676747-B2 Hepatitis B antiviral agents NOVIRA THERAPEUTICS, INC. (US) 2017-06-13 US disclosed
US-9061008-B2 Hepatitis B antiviral agents NOVIRA THERAPEUTICS, INC. (US) 2015-06-23 US disclosed
US-9061008-B2 Hepatitis B antiviral agents NOVIRA THERAPEUTICS, INC. (US) 2015-06-23 US disclosed
US-8785486-B2 Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors Janssen Pharmaceuticals, Inc. (US) 2014-07-22 US disclosed
US-8785486-B2 Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors Janssen Pharmaceuticals, Inc. (US) 2014-07-22 US disclosed
US-20110009441-A1 IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) 2011-01-13 US disclosed
US-20100144701-A1 Modulators of CB1 Receptors 7TM PHARMA A/S (DK) 2010-06-10 US disclosed
WO-2009062676-A2 IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) 2009-05-22 WO disclosed
US-4954511-A ALLEVIATING PAIN, TREATING DEPRESSION, CONVULSIONS AND HYPERTENSION HOECHST-ROUSSELL PHARMACEUTICALS INC. (US) 1990-09-04 US disclosed
US-4914204-A ANALGESICS, ANTIDEPRESSANTS, ANTICONVULSANTS, HYPOTENSIVE AGENTS HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1990-04-03 US disclosed
EP-0333027-A1 4-Pentafluorophenoxypiperidines, a process for their preparation and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1989-09-20 EP disclosed
US-4524207-A Process for preparing substituted 1,3-dihydrospiro[benzo(c)thiophene]s HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1985-06-18 US disclosed
US-4409229-A Antidepressive and tranquilizing substituted 1,3-dihydrospiro[benzo(c)thiophene]s HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) 1983-10-11 US disclosed
EP-0002283-B1 SUBSTITUTED 1,3-DIHYDROSPIRO (BENZO(C)THIOPHENES), PROCESS FOR THEIR PREPARATION AND THESE COMPOUNDS FOR USE AS MEDICAMENTS HOECHST AKTIENGESELLSCHAFT (DE) 1983-08-24 EP disclosed
EP-0002283-A1 Substituted 1,3-dihydrospiro (benzo(c)thiophenes), process for their preparation and these compounds for use as medicaments HOECHST AKTIENGESELLSCHAFT (DE) 1979-06-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10196376-B2 Hepatitis B antiviral agents HAVCR2, EIF2AK2, IRF3 OPRM1 3702/4885OPRD1 3394/4885OPRK1 2596/4885
US-20110009441-A1 IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS GRM2, GRM1, GRIA2 OPRM1 257/4885OPRD1 138/4885OPRK1 352/4885
US-20100144701-A1 Modulators of CB1 Receptors CNR1, CNR2, GPR6 OPRM1 81/4885OPRD1 78/4885OPRK1 98/4885
US-20210317134-A1 UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF USP7, SENP7, USP8 OPRM1 4147/4885OPRD1 3897/4885OPRK1 3916/4885
US-20170334882-A1 HEPATITIS B ANTIVIRAL AGENTS HAVCR2, EIF2AK2, IRF3 OPRM1 3702/4885OPRD1 3394/4885OPRK1 2596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.